Acute and chronic in vivo therapeutic resistance

Biochemical Pharmacology

Volumn 77, Issue 11, 2009, Pages 1665-1673

  Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Angiogenesis; Drug resistance; Hypoxia inducible factor; Immune privilege; Microenvironment; Transforming growth factor beta

Indexed keywords

ANGIOGENIC FACTOR; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ACIDOSIS; ACUTE PHASE RESPONSE; ANGIOGENESIS; ARTICLE; CANCER INVASION; CELL CULTURE; CELL GROWTH; CELL INFILTRATION; CELL MATURATION; CELL METABOLISM; CELL SURVIVAL; CHRONICITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HOST CELL; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; MESENCHYME CELL; NONHUMAN; PHENOTYPE; PHYSICAL STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL; STROMA; TUMOR CELL; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 64249086885     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.01.006     Document Type: Note

References (103)

1. Semenza G.L. Hypoxia and cancer. Cancer Metastasis Rev 26 (2007) 223-224
2. Vaupel P., and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26 (2007) 225-239
3. Dang C.V., Kim J.W., Gao P., and Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 8 (2008) 51-56
4. Moeller B.J., Richardson R.A., and Dewhirst M.W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26 (2007) 241-248
5. Dewhirst M.W., Cao Y., and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8 (2008) 425-437
6. Bristow R.G., and Hill R.P. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8 (2008) 180-192
7. Raguz S., and Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Brit J Cancer 99 (2008) 387-391
8. Liao D., and Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26 (2007) 281-290
9. Chan D.A., and Giaccia A.J. Hypoxia, gene expression and metastasis. Cancer Metastasis Rev 26 (2007) 333-339
10. Grigoryan R., Keshelava N., Anderson C., and Reynolds C.P. In vitro testing of chemosenstivity in physiologic hypoxia. In: Blumenthal R.D. (Ed). Methods in Molec Med 110: Chemosensitivity 1: In Vitro Assays (2007), Humana Press Inc., Totowa NJ 87-93
11. Yao K., Gietema J.A., Shida S., Selvakumaran M., Fonrose X., Haas N.B., et al. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Brit J Cancer 93 (2005) 1356-1363
12. Callaghan R., Crowley E., Potter S., and Kerr I.D. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48 (2008) 365-378
13. Shain K.H., and Dalton W.S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 1 (2001) 69-78
14. Kim J.W., Gao P., and Dang C.V. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 26 (2007) 291-298
15. Chen Z., Lu W., Garcia-Prieto C., and Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39 (2007) 267-274
16. Swietach P., Vaughan-Jones R.D., and Harris A.L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26 (2007) 299-310
17. Gillies R.J., and Gatenby R.A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 26 (2007) 311-317
18. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26 (2007) 333-339
19. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25 (2007) 4066-4074
20. Li Z.W., and Dalton W.S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 20 (2006) 333-342
21. Witz IP. Tumor microenvironment interactions: dangerous liaisons. In: George F, Vande Woude, George Klein, editors. Adv Cancer Res 2008;100:203-29.
22. Dong M., and Blobe G.C. Role of transforming growth factor-β in hematologic malignancies. Blood 107 (2006) 4589-4596
23. Inman G.J., and Allday M.J. Resistance to TGF-β1 correlates with a reduction of TGF-β type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 81 (2000) 1567-1578
24. Lukashev D., Ohta A., and Sitkovsky M. Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev 26 (2007) 273-279
25. Borger D.R., Mi Y., Gesiani G., Zyzak L.L., Batova A., Engin T.S.W., et al. Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-β. Virology 270 (2000) 397-407
26. Funasaka T., and Raz A. The role of autocrine motility factor in tumor and tumor microenvironment. Cancer Metastasis Rev 26 (2007) 725-735
27. Kim R., Emi M., Tanabe K., Uchida Y., and Toge T. The role of Fas ligand and transforming growth factor β in tumor progression. Cancer 100 (2004) 2281-2291
28. Chen M.L., Pittet M.J., Gorelik L., Flavell R.A., Weissleder R., von Boehmer H., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 102 (2005) 419-424
29. Teicher B.A. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20 (2001) 133-143
30. Bierie B., and Moses H.L. TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6 (2006) 506-520
31. Kang S.H., Bang Y.J., Im Y.H., Yang H.K., Lee D.A., Lee H.Y., et al. Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer. Oncogene 18 (1999) 7280-7286
32. Baldwin R.L., Tran H., and Karlan B.Y. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor β growth arrest independent of transforming growth factor β/smad signaling. Cancer Res 63 (2003) 1413-1419
33. Iyer S., Wang Z.G., Aktari M., Zhao W., and Seth P. Targeting TGFβ signaling for cancer therapy. Cancer Biol Ther 4 (2005) 261-266
34. Teicher B.A., Herman T.S., Holden S.A., Wang Y., Pfeffer M.R., Crawford J.M., et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247 (1990) 1457-1461
35. Teicher B.A., Maehara Y., Kakeji Y., Ara G., Keyes S.R., Wong J., et al. Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Inst J Cancer 71 (1997) 49-58
36. Teicher B.A., Holden S.A., Ara G., and Chen G. Transforming growth factor-β in in vivo resistance. Cancer Chemother Pharmacol 37 6 (1996) 601-609
37. Chorna I., Fedorenko O., Datsyuk L., and Stoika R. Expression of mRNA coding for TGF-β and its receptors in irradiated human breast carcinoma MCF-7 cells differing in their sensitivity to doxorubicin. Exp Oncol 27 (2005) 156-158
38. Turner S., Sherratt J.A., and Cameron D. Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFβ. J Theor Biol 229 (2004) 101-111
39. Stoika R., Yakymovych M., Souchelnytskyi S., and Yakymovych. Potential role of transforming growth factor β1 in drug resistance of tumor cells. Acta Biochim Polonica 50 (2003) 497-508
40. Utsunomiya Y., Hasegawa H., Yanagisawa K., and Fujita S. Enhancement of mdr1 gene expression by transforming growth factor-beta 1 in a new adriamycin-resistant human leukemia cell line ME-F2/ADM. Leukemia 11 (1997) 894-895
41. Mimeault M., and Batra S.K. Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol 18 (2007) 1605-1619
42. Muller A.J., and Scherle P.A. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6 (2006) 613-625
43. Teicher B.A. Transforming growth factor-β and the immune response to malignant disease. Clin Cancer Res 13 (2007) 6247-6251
44. Mempel T.R., Pittet M.J., Khazaie K., Weninger W., Weissieder R., von Boehmer H., et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25 (2006) 129-141
45. Khazaie K., and von Boehmer H. The impact of CD4+ CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin Cancer Biol 16 (2006) 124-136
46. Kretschmer K., Apostlou I., Jaeckel E., Khazaie K., and von Boehmer. Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev 212 (2006) 163-169
47. Fontenot J.D., and Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6 (2005) 331-337
48. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445 (2007) 931-935
49. Sitkovsky M.V., Kjaergaard J., Lukashev D., and Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14 (2008) 5947-5952
50. Lukashev D., Ohta A., and Sitkovsky M. Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Met Rev 26 (2007) 273-279
51. Murri A.M.A., Hilmy M., Bell J., Wilson C., McNicol A.M., Lannigan A., et al. The relationship between the systemic inflammatory response, tumor proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Brit J Cancer 99 (2008) 1013-1019
52. Mizukami Y., Kohgo Y., and Chung D.C. Hypoxia inducible factor-1-independent pathways in tumor angiogenesis. Clin Cancer Res 13 (2007) 5670-5678
53. Manning E.A., Ullman J.G.M., Leatherman J.M., Asquith J.M., Hansen T.R., Armstrong T.D., et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13 (2007) 3951-3959
54. Kerbel R.S. Tumor angiogenesis. New Engl J Med 358 (2008) 2039-2049
55. Hellmann K. Recognition of tumor blood vessel normalization as a new antiangiogenic concept. Nat Med 10 (2004) 329
56. Le Serve A.W., and Hellmann K. Metastases and the normalization of tumor blood vessels ay ICRF 159: a new type of drug action. Brit Med J 1 (1972) 597-601
57. Fukumura D., and Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvascul Res 74 (2007) 72-84
58. Teicher B.A., Holden S.A., Ara G., Alvarez Sotomayor E., Huang Z.D., Chen Y.-N., et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57 (1994) 920-925
59. Ellis L.M., and Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 8 (2008) 579-591
60. Murdoch C., Muthana M., Coffelt S.B., and Lewis C.E. The role of myeloid cells in the promotion of tumor angiogenesis. Nat Rev Cancer 8 (2008) 618-631
61. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008) 592-603
62. Dong D., Ko B., Baumeister P., Swenson S., Costa F., Markland F., et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 with in the tumor microenvironment. Cancer Res 65 (2005) 5785-5791
63. Avraamides C.J., Garmy-Susini B., and Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8 (2008) 604-617
64. Neufeld G., and Kessler O. The semaphorins: versatile regulators of tumor progression and tumor angiogenesis. Nat Rev Cancer 8 (2008) 632-645
65. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
66. Duda D.G., Jain R.K., and Willett C.G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25 (2007) 4033-4042
67. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., et al. Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature 446 (2007) 765-770
68. Hartmann T.N., Burger J.A., Glodek A., Fujii N., and Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24 (2005) 4462-4471
69. Das B., Tsuchida R., Malkin D., Koren G., Baruchel S., and Yeger. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26 (2008) 1818-1830
70. Postovit L.M., Margaryan N.V., Seftor E.A., Krischmann D.A., Lipavsky A., Wheaton W.W., et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA 105 (2008) 4329-4334
71. Blansfield J.A., Caragacianu D., Alexander III H.R., Tangrea M.A., Morita S.Y., Lorang D., et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14 (2008) 270-280
72. Potenta S., Zeisberg E., and Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Brit J Cancer 99 (2008) 1375-1379
73. Degrossoli A., and Giorgio S. Functional alterations in macrophages after hypoxia selection. Exp Biol Med 232 (2007) 88-95
74. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14 (2008) 518-527
75. San Francisco I.F., DeWolf W.C., Peehl D.M., and Olumi A.F. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer 112 (2004) 123-128
76. Hu M., Yao J., Carroll D.K., Weremowicz S., Chen H., Carrasco D., et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13 (2008) 394-406
77. Hayashi T., Hideshima T., Nguyen A.N., Munoz O., Podar K., Hamasaki M., et al. Transforming growth factor b receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10 (2004) 7540-7546
78. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat med 12 (2006) 895-904
79. Podsypanina K., Du Y.C.N., Jechlinger M., Beverly L.J., Hambardzuyan D.F., and Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321 (2008) 1841-1844
80. Sullivan R., and Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Mets Rev 26 (2007) 319-331
81. Tredan O., Gaimarini C.M., Patel K., and Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99 (2007) 1441-1454
82. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 199;5:662-68.
83. Gatenby R.A., and Gillies R.J. A microenvironmental model of carcinogenesis. Nat Rev Cancer 8 (2008) 56-61
84. Vonlaufen A., Phillips P.A., Xu Z., Goldstein D., Pirola R.C., Wilson J.S., et al. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res 68 (2008) 7707-7710
85. Ide T., Kitajima Y., Miyoshi A., Ohtsuka T., Mitsuno M., Ohtaka K., et al. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 14 (2007) 2600-2607
86. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., and Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14 (2007) 3629-3637
87. Kim M.P., and Gallick G.E. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14 (2008) 1284-1285
88. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development and disease. J Cell Biol 172 (2006) 973-981
89. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008) 704-715
90. Blick T., Widodo E., Hugo H., Waltham M., Lenburg M.E., Neve R.M., et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Mets 25 (2008) 629-642
91. Buck E., Eyzaguirre A., Barr S., Thompson S., Sennello R., Young D., et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6 (2007) 532-541
92. Frederick B.A., Helfrich B.A., Coldren C.D., Zheng D., Chan D., Bunn Jr. P.A., et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6 (2007) 1683-1691
93. Sabbah M., Emami S., Redeuilh G., Julien S., Prevost G., Zimber A., et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updates 11 (2008) 123-151
94. Teicher B.A., Kakeji Y., Ara G., Herbst R.S., and Northey D. Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 11 (1997) 453-462
95. Hazlehurst L.A., Enkemann S.A., Beam C.A., Argilagos R.F., Painter J., Shain K.H., et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 63 (2003) 7900-7906
96. Teicher B.A., Ara G., Keyes S.R., Herbst R.S., and Frei III E. Acute in vivo resistance in high-dose therapy. Clin Cancer Res 4 (1998) 483-491
97. Wu W., Luo Y., Sun C., Kuo P., Varga J., Xiang R., et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 66 (2006) 970-980
98. Gordan J.D., Thompson C.B., and Simon M.C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12 (2007) 108-113
99. Teicher B.A. In vivo resistance. In: Teicher B.A. (Ed). Cancer drug discovery and development: cancer drug resistance (2006), Humana Press Inc., Totowa, NJ 161-179
100. West C.M.L., Jones T., and Price P. The potential pf positron-emission tomography to study anticancer-drug resistance. Nat Rev Cancer 4 (2004) 457-469
101. Appelbaum F.R. Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today and tomorrow. J Clin Oncol 26 (2008) 2927-2929
102. Kamb A., Wee S., and Lengauer C. Why is cancer drug discovery so difficult?. Nat Rev Drug Discov 6 (2007) 115-120
103. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Nature 81 (2007) 164-169